Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Shaw, Alice
Item TypeName
Academic Article Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.
Academic Article Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung.
Academic Article Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis.
Academic Article Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Academic Article Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
Academic Article Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
Academic Article Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
Academic Article ALK in lung cancer: past, present, and future.
Academic Article Targeting anaplastic lymphoma kinase in lung cancer.
Academic Article Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Academic Article ROS1 rearrangements define a unique molecular class of lung cancers.
Academic Article Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Academic Article Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
Academic Article Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Academic Article Crizotinib and testing for ALK.
Academic Article Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.
Academic Article Crizotinib.
Academic Article Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Academic Article Are anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer prognostic, predictive, or both?
Academic Article Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Academic Article Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
Concept Creatine Kinase
Concept Protein Kinase Inhibitors
Concept Cyclin-Dependent Kinase Inhibitor p16
Concept MAP Kinase Signaling System
Concept MAP Kinase Kinase 1
Academic Article Hypogonadism related to crizotinib therapy: implications for patient care.
Academic Article ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Academic Article Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Academic Article Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Academic Article Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Academic Article Tyrosine kinase gene rearrangements in epithelial malignancies.
Academic Article Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.
Academic Article Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
Academic Article The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer.
Academic Article Ceritinib in ALK-rearranged non-small-cell lung cancer.
Academic Article Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.
Academic Article The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Academic Article Ceritinib in ALK-rearranged non-small-cell lung cancer.
Academic Article ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Academic Article Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Academic Article Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Academic Article Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Academic Article Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.
Academic Article Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Academic Article Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Academic Article Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Academic Article Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
Academic Article Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Academic Article Complex renal cysts associated with crizotinib treatment.
Academic Article Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
Academic Article Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
Academic Article Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Academic Article PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
Academic Article Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
Academic Article Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma.
Academic Article Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Academic Article Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Academic Article Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.
Academic Article Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Academic Article P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Academic Article Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Academic Article Crizotinib Resensitization by Compound Mutation.
Academic Article 1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial.
Academic Article Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.
Academic Article Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Academic Article Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Academic Article Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter?
Academic Article Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.
Academic Article Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Academic Article Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping.
Academic Article Crizotinib resistance: implications for therapeutic strategies.
Grant Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors
Academic Article EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Academic Article Resisting Resistance: Targeted Therapies in Lung Cancer.
Academic Article Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Academic Article Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Academic Article Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Academic Article ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Academic Article Targeting ALK: Precision Medicine Takes on Drug Resistance.
Academic Article KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.
Academic Article Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.
Academic Article Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Academic Article J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer.
Academic Article Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.
Academic Article Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Academic Article Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Academic Article Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Academic Article Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.
Academic Article Fast, Food and Ceritinib in ALK-Positive NSCLC.
Academic Article Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Academic Article Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.
Academic Article Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
Academic Article Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
Academic Article ALK inhibitors in non-small cell lung cancer: how many are needed and how should they be sequenced?
Academic Article Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Academic Article Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.
Academic Article SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
Academic Article Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.
Academic Article Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Academic Article Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
Academic Article Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.
Academic Article Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
Academic Article Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Academic Article Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.
Academic Article Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
Academic Article Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
Academic Article Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Academic Article Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
Academic Article Refining precision cancer therapy in ALK-positive NSCLC.
Academic Article Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Academic Article Clinical Management of Adverse Events Associated with Lorlatinib.
Academic Article ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Academic Article Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
Academic Article Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.
Academic Article The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Academic Article Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.
Academic Article Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors.
Academic Article Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
Academic Article ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.
Academic Article Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC.
Academic Article Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Academic Article Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Academic Article Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer.
Academic Article Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies.
Academic Article MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Academic Article Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Academic Article First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Academic Article Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
Academic Article A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
Academic Article Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
Search Criteria
  • Elongation Factor 2 Kinase
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.